Intec Pharma Ltd (NASDAQ:NTEC) – Research analysts at Oppenheimer issued their FY2022 earnings per share estimates for shares of Intec Pharma in a report issued on Monday. Oppenheimer analyst J. Olson forecasts that the biotechnology company will earn $0.31 per share for the year. Oppenheimer currently has a “Buy” rating and a $15.00 target price on the stock.
A number of other equities analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Intec Pharma in a research note on Monday. Ladenburg Thalmann Financial Services began coverage on Intec Pharma in a research note on Wednesday, February 28th. They set a “buy” rating for the company. Zacks Investment Research cut Intec Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Maxim Group set a $8.00 target price on Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.00.
Large investors have recently bought and sold shares of the company. Deutsche Bank AG grew its position in shares of Intec Pharma by 59.2% during the 4th quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 42,867 shares during the period. Caxton Corp acquired a new stake in shares of Intec Pharma during the 3rd quarter valued at about $681,000. Renaissance Technologies LLC grew its position in shares of Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after acquiring an additional 53,100 shares during the period. Pura Vida Investments LLC acquired a new stake in shares of Intec Pharma during the 3rd quarter valued at about $895,000. Finally, Millennium Management LLC acquired a new stake in shares of Intec Pharma during the 4th quarter valued at about $1,392,000. Hedge funds and other institutional investors own 41.39% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.